[go: up one dir, main page]

AR102108A1 - DRY POWDER FOR A FORMULATION TO INHALATE THAT HAS IMPROVED STABILITY OF COMBINED ACTIVE PRINCIPLES - Google Patents

DRY POWDER FOR A FORMULATION TO INHALATE THAT HAS IMPROVED STABILITY OF COMBINED ACTIVE PRINCIPLES

Info

Publication number
AR102108A1
AR102108A1 ARP150103125A ARP150103125A AR102108A1 AR 102108 A1 AR102108 A1 AR 102108A1 AR P150103125 A ARP150103125 A AR P150103125A AR P150103125 A ARP150103125 A AR P150103125A AR 102108 A1 AR102108 A1 AR 102108A1
Authority
AR
Argentina
Prior art keywords
dry powder
formulation
weight
inhalate
combined active
Prior art date
Application number
ARP150103125A
Other languages
Spanish (es)
Inventor
Soo Woo Jong
Hyun Park Jae
Min Yoon Young
Jun Cho Hyuk
Soo Kim Kyeong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR102108A1 publication Critical patent/AR102108A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un polvo seco para una formulación para inhalar y una formulación para inhalar que incluye el polvo seco. El polvo seco incluye: al menos dos principios activos combinados seleccionados a partir del grupo constituido por salmeterol o una de sus sales farmacéuticamente aceptables, tiotropio o una de sus sales farmacéuticamente aceptables y fluticasona o una de sus sales farmacéuticamente aceptables; y un diluyente, como complejo de lactosa, donde el diluyente incluye entre aproximadamente un 0.1% en peso y aproximadamente un 50% en peso de polvo micronizado que tiene un diámetro de partícula promedio (X₅₀) igual o inferior a aproximadamente 30 mm en función del peso total del diluyente, de modo que la estabilidad de al menos uno de los principios activos es superior a la de un polvo seco que tiene un contenido en polvo micronizado superior a un 50% en peso. Método.A dry powder for an inhalation formulation and an inhalation formulation that includes dry powder. The dry powder includes: at least two combined active ingredients selected from the group consisting of salmeterol or one of its pharmaceutically acceptable salts, tiotropium or one of its pharmaceutically acceptable salts and fluticasone or one of its pharmaceutically acceptable salts; and a diluent, as a lactose complex, where the diluent includes between about 0.1% by weight and about 50% by weight of micronized powder having an average particle diameter (X₅₀) equal to or less than about 30 mm depending on the total weight of the diluent, so that the stability of at least one of the active ingredients is superior to that of a dry powder having a micronized powder content exceeding 50% by weight. Method.

ARP150103125A 2014-09-30 2015-09-29 DRY POWDER FOR A FORMULATION TO INHALATE THAT HAS IMPROVED STABILITY OF COMBINED ACTIVE PRINCIPLES AR102108A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140132006 2014-09-30

Publications (1)

Publication Number Publication Date
AR102108A1 true AR102108A1 (en) 2017-02-01

Family

ID=55630875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103125A AR102108A1 (en) 2014-09-30 2015-09-29 DRY POWDER FOR A FORMULATION TO INHALATE THAT HAS IMPROVED STABILITY OF COMBINED ACTIVE PRINCIPLES

Country Status (5)

Country Link
KR (1) KR20160038767A (en)
AR (1) AR102108A1 (en)
TW (1) TW201618759A (en)
UY (1) UY36336A (en)
WO (1) WO2016052897A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
WO2005087192A2 (en) * 2004-03-12 2005-09-22 Cipla Limited Salmeterol inhalation formulations
TR201000681A2 (en) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Dry powder formulations inhaled.
KR20130140358A (en) * 2012-06-14 2013-12-24 한미약품 주식회사 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing the same

Also Published As

Publication number Publication date
KR20160038767A (en) 2016-04-07
WO2016052897A1 (en) 2016-04-07
TW201618759A (en) 2016-06-01
UY36336A (en) 2016-04-01

Similar Documents

Publication Publication Date Title
UY36275A (en) AMINOPIRIMIDINYL COMPOUNDS
CL2016001889A1 (en) (2s) -n - [(1s) -1-cyano-2-phenylethyl] -1,4-oxazepan-2-carboxamides as dipeptidyl peptidase 1 inhibitors.
SV2016005236A (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBE AND ROSUVASTATIN
CL2016002148A1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutically acceptable pharmaceutical compositions and compositions prepared therefrom.
MX2021008113A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AN IL-4R ANTAGONIST FOR USE IN THE TREATMENT OF ASTHMA.
CL2016002812A1 (en) Use of 3-2,3,5,6-tetrafluoro-3-trifluoromethoxy-biphenyl-4-ylcarbamoyl-thiophene-2-carboxylic acid to prepare a medicament useful for treating an eye disease that is uveitis, dry eye or caused by a adenovirus composition formulation.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
MX2017006268A (en) INTRANASAL ADMINISTRATION.
SG10201805024YA (en) Methods useful in the synthesis of halichondrin b analogs
MX2014014711A (en) N-aryltriazole compounds as lpar antagonists.
CL2015002334A1 (en) Sweet Taste Modifier
CL2016001543A1 (en) Isocromen derivatives as inhibitors of phosphoinositido-3 kinases.
CL2017000742A1 (en) Mono or disubstituted Indoles as inhibitors of dengue virus replication
MX2017009309A (en) DERIVATIVES OF INDOL MONO OR DISPOSED AS INHIBITORS OF THE REPLICATION OF DENGUE VIRUSES.
IN2013MU03577A (en)
MA40583A (en) Novel soluble guanylate cyclase activators and their use
MX2017004440A (en) AN INHALABLE RAPAMYCIN FORMULATION FOR THE TREATMENT OF PULMONARY HYPERTENSION.
CL2018003338A1 (en) Physiologically balanced injectable formulations of fosnetupitant.
CL2016001094A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia.
CL2016000300A1 (en) Therapeutic methods
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
MX2015008538A (en) COMPOSITION THAT INCLUDES A PURIFIED EXTRACT THAT IS ISOLATED FROM PSEUDOLYSIMACHION ROTUNDUM VAR. SUBINTEGRUM CONTAINING AN ABUNDANT AMOUNT OF ACTIVE INGREDIENT OR ISOLATED COMPOUNDS OF THE SAME, AS AN ACTIVE INGREDIENT TO PREVENT OR TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ITS USE.
MX385513B (en) PHARMACEUTICAL COMPOSITIONS INCLUDING SAFINAMIDE.
AR102108A1 (en) DRY POWDER FOR A FORMULATION TO INHALATE THAT HAS IMPROVED STABILITY OF COMBINED ACTIVE PRINCIPLES
MX2017013633A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO PHARMACES FROM PARTICLES.

Legal Events

Date Code Title Description
FB Suspension of granting procedure